News
May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback